Abstract
The ability of alpha-fetoprotein (AFP), derived from mouse amniotic fluid, to alter qualitative and quantitative characteristics of pristane-induced plasmacytomas and the carcinogenic action of 3-methylcholanthrene (MCA) and 7,12-dimethylbenz[a]anthracene (DMBA) was studied and compared to analogous treatment with murine albumin and transferrin in BALB/c mice. Pharmacologic doses of 200 μg AFP ip three times per week had no effect on either latency period or tumor incidence in mice given injections of MCA and DMBA when compared to albumin treated and transferrin-treated controls. Moreover, this lack of influence of AFP was found at high and low dosages of the carcinogens. In contrast AFP, but neither albumin nor transferrin, accelerated the appearance of plasmacytomas in pristane-primed BALB/c mice. Moreover, the immunoglobulin class of plasmacytomas of mice given AFP injections was qualitatively altered, and an increase in IgM and IgG2b plasmacytomas was noted. These effects occurred at serum AFP levels of 90-260 μg/ml. Although these results should not be used to support a normal physiologic role of AFP in immune regulation, they are similar to previous observations of suppression mediated by the alpha-globulin fraction of normal serum and suggest that pharmacologic dosages of AFP may be useful in the study of select, possibly thymus-dependent, immune responses.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 145-149 |
| Number of pages | 5 |
| Journal | Journal of the National Cancer Institute |
| Volume | 64 |
| Issue number | 1 |
| State | Published - 1980 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Accelerated plasmacytoma formation in mice treated with alpha-fetoprotein. / Gershwin, M. Eric; Castles, J. J.; Makishima, R.
In: Journal of the National Cancer Institute, Vol. 64, No. 1, 1980, p. 145-149.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Accelerated plasmacytoma formation in mice treated with alpha-fetoprotein
AU - Gershwin, M. Eric
AU - Castles, J. J.
AU - Makishima, R.
PY - 1980
Y1 - 1980
N2 - The ability of alpha-fetoprotein (AFP), derived from mouse amniotic fluid, to alter qualitative and quantitative characteristics of pristane-induced plasmacytomas and the carcinogenic action of 3-methylcholanthrene (MCA) and 7,12-dimethylbenz[a]anthracene (DMBA) was studied and compared to analogous treatment with murine albumin and transferrin in BALB/c mice. Pharmacologic doses of 200 μg AFP ip three times per week had no effect on either latency period or tumor incidence in mice given injections of MCA and DMBA when compared to albumin treated and transferrin-treated controls. Moreover, this lack of influence of AFP was found at high and low dosages of the carcinogens. In contrast AFP, but neither albumin nor transferrin, accelerated the appearance of plasmacytomas in pristane-primed BALB/c mice. Moreover, the immunoglobulin class of plasmacytomas of mice given AFP injections was qualitatively altered, and an increase in IgM and IgG2b plasmacytomas was noted. These effects occurred at serum AFP levels of 90-260 μg/ml. Although these results should not be used to support a normal physiologic role of AFP in immune regulation, they are similar to previous observations of suppression mediated by the alpha-globulin fraction of normal serum and suggest that pharmacologic dosages of AFP may be useful in the study of select, possibly thymus-dependent, immune responses.
AB - The ability of alpha-fetoprotein (AFP), derived from mouse amniotic fluid, to alter qualitative and quantitative characteristics of pristane-induced plasmacytomas and the carcinogenic action of 3-methylcholanthrene (MCA) and 7,12-dimethylbenz[a]anthracene (DMBA) was studied and compared to analogous treatment with murine albumin and transferrin in BALB/c mice. Pharmacologic doses of 200 μg AFP ip three times per week had no effect on either latency period or tumor incidence in mice given injections of MCA and DMBA when compared to albumin treated and transferrin-treated controls. Moreover, this lack of influence of AFP was found at high and low dosages of the carcinogens. In contrast AFP, but neither albumin nor transferrin, accelerated the appearance of plasmacytomas in pristane-primed BALB/c mice. Moreover, the immunoglobulin class of plasmacytomas of mice given AFP injections was qualitatively altered, and an increase in IgM and IgG2b plasmacytomas was noted. These effects occurred at serum AFP levels of 90-260 μg/ml. Although these results should not be used to support a normal physiologic role of AFP in immune regulation, they are similar to previous observations of suppression mediated by the alpha-globulin fraction of normal serum and suggest that pharmacologic dosages of AFP may be useful in the study of select, possibly thymus-dependent, immune responses.
UR - http://www.scopus.com/inward/record.url?scp=0018916894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018916894&partnerID=8YFLogxK
M3 - Article
VL - 64
SP - 145
EP - 149
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 1
ER -